Epix Pharmaceuticals (NASDAQ:[[ticker:EPIX]]), a Lexington, MA-based biopharmaceutical firm, announced Thursday that it is reducing its work force by 23 percent and “narrowing” the focus of its R&D. The company, which plans to continue developing its lead drugs for Alzheimer’s disease and respiratory conditions, says it expects the cuts to reduce its annual expenses by about $3 million.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
